ICP-Healthcare

As China’s pharmaceutical and medical device players are starting to show scale, they are bound to consolidate. Recently, the majority of China’s deal activity was related to drug manufacturing assets and drug commercialization, which is different to several years ago when CRO services were the name of the game. Many local players have reshuffled their investment portfolios and acquired other domestic companies, driving the consolidation forward in terms of production capacities as well as sales & distribution channels. On the other hand, foreign pharma players realized that China has become the world’s second largest drug market that keeps growing at 15 – 18% p.a., and they keep trying to find a fast entry or expansion in the Chinese market via M&A. In the medical device sector, larger foreign players have started to acquire the domestic top players (as very evident in orthopedics), not the least to bridge registration issues of their import portfolios. With a domestic market continuing to grow at fast speed, deal valuations will remain higher compared to other industries in the years to come.

Buyer advised by

InterChina

Buyer advised by

InterChina

Buyer advised by

InterChina

Buyer advised by

InterChina

Medichem advised by

InterChina

BD advised by

InterChina